HN3Q.F · Nova Mentis Life Science Corp

-

Please sign in to comment on HN3Q.F

1 Comment

Admin

4 years ago

Nova Mentis Life Science Corp is currently in a long term downtrend where the price is trading 48.9% below its 200 day moving average.

From a valuation standpoint, the stock is 76.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 309.2.

Nova Mentis Life Science Corp's total revenue rose by inf% to $1K since the same quarter in the previous year.

Its net income has dropped by 61.2% to $-554K since the same quarter in the previous year.

Finally, its free cash flow grew by 36.7% to $-144K since the same quarter in the previous year.

Based on the above factors, Nova Mentis Life Science Corp gets an overall score of 3/5.

Exchange	F
Sector	Healthcare
Industry	Biotechnology
CurrencyCode	EUR
ISIN	CA66980V1067

Beta	0.63
Market Cap	793K
PE Ratio	None
Target Price	None
Dividend Yield	None

ABOUT

Nova Mentis Life Science Corp

Nova Mentis Life Science Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is based in Vancouver, Canada.

HN3Q.F · Nova Mentis Life Science Corp

-

Nova Mentis Life Science Corp

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Nova Mentis Life Science Corp using a moving average strategy